The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | Venetoclax & AML
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, touches on the promising data seen in use of venetoclax for the treatment of acute meyloid leukemia (AML), the optimization of this treatment for different patient populations and it’s use in the post-transplant setting. Cusatuzumab and magrolimab are also discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
